Luigi De Petris

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: STUDIES IN HEALTH TECHNOLOGY AND INFORMATICS. 2023;302:18-22

Application of Process Mining for Modelling Small Cell Lung Cancer Prognosis.

Marzano L; Meijer S; Dan A; Tendler S; De Petris L; Lewensohn R; Raghothama J; Darwich AS
Article: PHARMACEUTICS. 2023;15(4):1148

A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.

Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Manouchehri Doulabi E; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(10):2064-2078

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients.

Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2022;15(10):2437-2447

A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer study.

Marzano L; Darwich AS; Tendler S; Dan A; Lewensohn R; De Petris L; Raghothama J; Meijer S
Article: CANCERS. 2022;14(14):3430

Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer.

Kosibaty Z; Brustugun OT; Zwicky Eide IJ; Tsakonas G; Grundberg O; De Petris L; McGowan M; Hydbring P; Ekman S
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(5):722-734

Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer.

Kaźmierczak D; Eide IJZ; Gencheva R; Lai Y; Lewensohn R; Tsakonas G; Grundberg O; de Petris L; McGowan M; Brustugun OT; Ekman S; Hydbring P
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2022;130(4):513-521

The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes.

Björn N; Jakobsen I; Udagawa C; Brandén E; Koyi H; Lewensohn R; De Petris L; Zembutsu H; Gréen H
Article: NATURE CANCER. 2022;3(2):251-261

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Braña I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Cancer Core Europe consortium; Balmaña J; Apolone G; Caldas C; Bergh J; Ernberg I; Fröhling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtiö J
Article: MOLECULAR ONCOLOGY. 2021;15(11):2941-2957

Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage.

Franzén B; Viktorsson K; Kamali C; Darai-Ramqvist E; Grozman V; Arapi V; Hååg P; Kaminskyy VO; Hydbring P; Kanter L; Nyrén S; Ekman S; De Petris L; Lewensohn R
Article: CANCERS. 2021;13(13):3151

High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC.

Tsakonas G; Martín-Bernabé A; Rounis K; Moreno-Ruiz P; Botling J; De Petris L; Ylipää A; Mezheyeuski A; Micke P; Östman A; Ekman S
Article: ANNALS OF DIAGNOSTIC PATHOLOGY. 2021;51:151701

Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.

Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
Article: CANCERS. 2021;13(7):1562

Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy.

Rounis K; Skribek M; Makrakis D; De Petris L; Agelaki S; Ekman S; Tsakonas G
Article: EUROPEAN JOURNAL OF CANCER. 2021;145:245-254

Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.

Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Article: CANCERS. 2021;13(4):922

Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR.

Stiller C; Viktorsson K; Paz Gomero E; Hååg P; Arapi V; Kaminskyy VO; Kamali C; De Petris L; Ekman S; Lewensohn R; Karlström AE
Article: INTERNATIONAL JOURNAL OF CANCER. 2021;148(1):238-251

A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.

Liljedahl H; Karlsson A; Oskarsdottir GN; Salomonsson A; Brunnström H; Erlingsdottir G; Jönsson M; Isaksson S; Arbajian E; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J
Article: CANCERS. 2020;12(12):E3707-3707

Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting.

Skribek M; Rounis K; Makrakis D; Agelaki S; Mavroudis D; De Petris L; Ekman S; Tsakonas G
Article: LUNG CANCER. 2020;147:106-114

Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.

Svedberg A; Björn N; Sigurgeirsson B; Pradhananga S; Brandén E; Koyi H; Lewensohn R; De Petris L; Apellániz-Ruiz M; Rodríguez-Antona C; Lundeberg J; Gréen H
Article: NPJ SYSTEMS BIOLOGY AND APPLICATIONS. 2020;6(1):25

Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.

Björn N; Badam TVS; Spalinskas R; Brandén E; Koyi H; Lewensohn R; De Petris L; Lubovac-Pilav Z; Sahlén P; Lundeberg J; Gustafsson M; Gréen H
Article: CANCERS. 2020;12(7):E1804-1804

ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases.

Tsakonas G; Kamali C; De Petris L; Friesland S; Lewensohn R; Ekman S
Article: NATURE MEDICINE. 2020;26(5):665-671

Caring for patients with cancer in the COVID-19 era.

van de Haar J; Hoes LR; Coles CE; Seamon K; Fröhling S; Jäger D; Valenza F; de Braud F; De Petris L; Bergh J; Ernberg I; Besse B; Barlesi F; Garralda E; Piris-Giménez A; Baumann M; Apolone G; Soria JC; Tabernero J; Caldas C; Voest EE
Article: ACTA ONCOLOGICA. 2020;59(4):388-394

Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.

Tendler S; Zhan Y; Pettersson A; Lewensohn R; Viktorsson K; Fang F; De Petris L
Article: PHARMACOGENOMICS JOURNAL. 2020;20(2):179-191

Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.

Björn N; Sigurgeirsson B; Svedberg A; Pradhananga S; Brandén E; Koyi H; Lewensohn R; de Petris L; Apellániz-Ruiz M; Rodríguez-Antona C; Lundeberg J; Gréen H
Article: LUNG CANCER. 2020;139:111-117

Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study.

Tendler S; Holmqvist M; Wagenius G; Lewensohn R; Lambe M; De Petris L
Article: LUNG CANCER. 2020;139:22-27

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

Ou S-HI; Gadgeel SM; Barlesi F; Yang JC-H; De Petris L; Kim D-W; Govindan R; Dingemans A-M; Crino L; Léna H; Popat S; Ahn JS; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos PN; Shaw AT
Article: PLOS ONE. 2020;15(10):e0240973

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.

Tendler S; Kanter L; Lewensohn R; Ortiz-Villalón C; Viktorsson K; De Petris L
Article: SCIENTIFIC REPORTS. 2019;9(1):10163

Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC.

Kilvaer TK; Rakaee M; Hellevik T; Vik J; Petris LD; Donnem T; Strell C; Ostman A; Busund L-TR; Martinez-Zubiaurre I
Article: SCIENTIFIC REPORTS. 2019;9(1):5207

A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer.

Karlsson A; Cirenajwis H; Ericson-Lindquist K; Brunnström H; Reuterswärd C; Jönsson M; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Micke P; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J
Article: LUNG CANCER. 2018;124:45-52

Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression.

Hydbring P; De Petris L; Zhang Y; Brandén E; Koyi H; Novak M; Kanter L; Hååg P; Hurley J; Tadigotla V; Zhu B; Skog J; Viktorsson K; Ekman S; Lewensohn R
Article: LUNG CANCER. 2018;120:75-81

Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.

Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Article: ACTA ONCOLOGICA. 2018;57(2):231-238

Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer.

Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
Article: JOURNAL OF THORACIC ONCOLOGY. 2017;12(10):1552-1560

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.

Yang JC-H; Ou S-HI; De Petris L; Gadgeel S; Gandhi L; Kim D-W; Barlesi F; Govindan R; Dingemans A-MC; Crino L; Lena H; Popat S; Ahn JS; Dansin E; Golding S; Bordogna W; Balas B; Morcos PN; Zeaiter A; Shaw AT
Article: CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT. 2017;6(3):280-291

Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.

Morcos PN; Cleary Y; Guerini E; Dall G; Bogman K; De Petris L; Viteri S; Bordogna W; Yu L; Martin-Facklam M; Phipps A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(34):4079-4085

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Gadgeel SM; Shaw AT; Govindan R; Gandhi L; Socinski MA; Camidge DR; De Petris L; Kim D-W; Chiappori A; Moro-Sibilot DL; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; Yang JC-H; Han J-Y; Bordogna W; Golding S; Zeaiter A; Ou S-HI
Article: ONCOTARGET. 2016;7(37):60332-60347

Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.

Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Hååg P; Viktorsson K
Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(7):661-668

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Ou S-HI; Ahn JS; De Petris L; Govindan R; Yang JC-H; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim D-W
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2016;94(3):612-620

Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Warner A; Dahele M; Hu B; Palma DA; Senan S; Oberije C; Tsujino K; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; De Ruyck K; De Dios NR; Bradley JD; Rodrigues G
Article: CLINICAL CANCER RESEARCH. 2016;22(2):366-373

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.

Gréen H; Hasmats J; Kupershmidt I; Edsgärd D; de Petris L; Lewensohn R; Blackhall F; Vikingsson S; Besse B; Lindgren A; Brandén E; Koyi H; Peterson C; Lundeberg J
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2015;91(1):133-139

Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.

Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
Article: GENES CHROMOSOMES & CANCER. 2013;52(10):895-911

miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.

Salim H; Arvanitis A; de Petris L; Kanter L; Hååg P; Zovko A; Özata DM; Lui W-O; Lundholm L; Zhivotovsky B; Lewensohn R; Viktorsson K
Article: JOURNAL OF PROTEOME RESEARCH. 2013;12(9):3934-3943

Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism.

Pernemalm M; De Petris L; Branca RM; Forshed J; Kanter L; Soria J-C; Girard P; Validire P; Pawitan Y; van den Oord J; Lazar V; Påhlman S; Lewensohn R; Lehtiö J
Article: ACTA ONCOLOGICA. 2013;52(6):1189-1194

Validation of the 7th TNM classification for non-small cell lung cancer: a retrospective analysis on prognostic implications for operated node-negative cases.

Bergman P; Brodin D; Lewensohn R; de Petris L
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2013;85(2):444-450

Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.

Palma DA; Senan S; Tsujino K; Barriger RB; Rengan R; Moreno M; Bradley JD; Kim TH; Ramella S; Marks LB; De Petris L; Stitt L; Rodrigues G
Article: EUROPEAN JOURNAL OF CANCER. 2011;47(1):131-137

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer.

De Petris L; Brandén E; Herrmann R; Sanchez BC; Koyi H; Linderholm B; Lewensohn R; Linder S; Lehtiö J
Article: PROTEOME SCIENCE. 2010;8:9

A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants.

De Petris L; Pernemalm M; Elmberger G; Bergman P; Orre L; Lewensohn R; Lehtiö J
Article: PROTEOMICS. 2009;9(13):3414-3424

Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion.

Pernemalm M; De Petris L; Eriksson H; Brandén E; Koyi H; Kanter L; Lewensohn R; Lehtiö J
Article: LUNG CANCER. 2009;63(3):410-417

Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.

De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Article: JOURNAL OF THORACIC ONCOLOGY. 2008;3(4):430-440

Second-line treatment of advanced non-small cell lung cancer.

Gridelli C; Ardizzoni A; Ciardiello F; Hanna N; Heymach JV; Perrone F; Rosell R; Shepherd FA; Thatcher N; Vansteenkiste J; De Petris L; Di Maio M; De Marinis F
Article: ANNALS OF ONCOLOGY. 2005;16 Suppl 4:iv116-iv122

Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.

De Marinis F; Gebbia V; De Petris L
Article: MEDICAL ONCOLOGY. 2005;22(4):375-381

Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.

De Petris L; Lax I; Sirzén F; Friesland S
Article: TUMORI JOURNAL. 2004;3(4):S50-S51

[The role of adjuvant chemotherapy in the treatment of early stage NSCLC after radical surgery].

De Marinis F; De Petris L
Article: MEDICAL ONCOLOGY. 2004;21(1):49-52

Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates.

De Petris L; Bergfeldt K; Hising C; Lundqvist A; Tholander B; Pisa P; van der Zanden HGM; Masucci G
Article: GIORNALE DI CHIRURGIA. 2002;23(10):379-382

[Peritoneal papillary serous carcinoma: clinical report].

Stagnitti F; Mongardini M; Schillaci F; Scirocchi R; De Petris L; Malizia A; Marenga G; Patrizi V; Priore FM; Corona F; Tiberi R; Di Placido M; Calderisi MD; Longo F
Visa fler

Alla övriga publikationer

Review: LIFE-BASEL. 2022;12(6):880

Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies.

Rounis K; Makrakis D; Gioulbasanis I; Ekman S; De Petris L; Mavroudis D; Agelaki S
Corrigendum: NATURE CANCER. 2022;3(5):649

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Braña I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Cancer Core Europe consortium; Balmaña J; Apolone G; Caldas C; Bergh J; Ernberg I; Fröhling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtiö J
Corrigendum: NATURE MEDICINE. 2020;26(7):1146

Author Correction: Caring for patients with cancer in the COVID-19 era.

van de Haar J; Hoes LR; Coles CE; Seamon K; Fröhling S; Jäger D; Valenza F; de Braud F; De Petris L; Bergh J; Ernberg I; Besse B; Barlesi F; Garralda E; Piris-Giménez A; Baumann M; Apolone G; Soria JC; Tabernero J; Caldas C; Voest EE
Letter: NATURE MEDICINE. 2020;26(7):992-994

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal.

Tamborero D; Dienstmann R; Rachid MH; Boekel J; Baird R; Braña I; De Petris L; Yachnin J; Massard C; Opdam FL; Schlenk R; Vernieri C; Garralda E; Masucci M; Villalobos X; Chavarria E; Cancer Core Europe consortium; Calvo F; Fröhling S; Eggermont A; Apolone G; Voest EE; Caldas C; Tabernero J; Ernberg I; Rodon J; Lehtiö J
Letter: ACTA ONCOLOGICA. 2020;59(1):28-32

Analysis of human papillomaviruses and human polyomaviruses in lung cancer from Swedish never-smokers.

Ramqvist T; Ortiz-Villalon C; Brandén E; Koyi H; de Petris L; Wagenius G; Brodin O; Reuterswärd C; Dalianis T; Jönsson M; Staaf J; Lewensohn R; Planck M
Corrigendum: LUNG CANCER. 2018;123:178-179

Corrigendum to "Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden" [Lung Cancer 120 (June) (2018) 75-81].

Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Review: CANCER TREATMENT REVIEWS. 2017;54:122-131

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.

Tsakonas G; De Petris L; Ekman S
Review: ESMO OPEN. 2016;1(5):e000097

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir N; Lotz J-P; Österlund P; Pavlidis N; Purkalne G; Awada A; Banerjee S; Bhatia S; Bogaerts J; Buckner J; Cardoso F; Casali P; Chu E; Close JL; Coiffier B; Connolly R; Coupland S; De Petris L; De Santis M; de Vries EGE; Dizon DS; Duff J; Duska LR; Eniu A; Ernstoff M; Felip E; Fey MF; Gilbert J; Girard N; Glaudemans AWJM; Gopalan PK; Grothey A; Hahn SM; Hanna D; Herold C; Herrstedt J; Homicsko K; Jones DV; Jost L; Keilholz U; Khan S; Kiss A; Köhne C-H; Kunstfeld R; Lenz H-J; Lichtman S; Licitra L; Lion T; Litière S; Liu L; Loehrer PJ; Markham MJ; Markman B; Mayerhoefer M; Meran JG; Michielin O; Moser EC; Mountzios G; Moynihan T; Nielsen T; Ohe Y; Öberg K; Palumbo A; Peccatori FA; Pfeilstöcker M; Raut C; Remick SC; Robson M; Rutkowski P; Salgado R; Schapira L; Schernhammer E; Schlumberger M; Schmoll H-J; Schnipper L; Sessa C; Shapiro CL; Steele J; Sternberg CN; Stiefel F; Strasser F; Stupp R; Sullivan R; Tabernero J; Travado L; Verheij M; Voest E; Vokes E; Von Roenn J; Weber JS; Wildiers H; Yarden Y
Review: JOURNAL OF INTERNAL MEDICINE. 2015;278(6):545-570

The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer.

Tobin NP; Foukakis T; De Petris L; Bergh J
Review: LUNG CANCER. 2012;76(3):269-279

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.

Gridelli C; de Marinis F; Di Maio M; Ardizzoni A; Belani CP; Cappuzzo F; Ciardiello F; Fidias P; Paz-Ares L; Perrone F; Pirker R; De Petris L; Stahel R
Review: JOURNAL OF PROTEOMICS. 2010;73(10):1851-1863

Lung cancer proteomics, clinical and technological considerations.

Lehtiö J; De Petris L
Review: LUNG CANCER. 2010;68(3):319-331

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C; Ardizzoni A; Douillard J-Y; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F
Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2007;2(8):S356-S357

Mass spectrometry profiling of low molecular weight platelet Proteome for the detection of lung cancer specific biomarkers

De Petris L; Pernemalm M; Branden E; Koyi H; Forshed J; Sundelin B; Lewensohn R; Lehtio J
Published conference paper: ANNALS OF ONCOLOGY. 2006;17 Suppl 5:v68-v71

Second-line chemotherapy for non-small cell lung cancer.

De Marinis F; De Santis S; De Petris L
Published conference paper: ANNALS OF ONCOLOGY. 2006;17 Suppl 2:ii36-ii41

Treatment of advanced non-small cell lung cancer.

De Petris L; Crinò L; Scagliotti GV; Gridelli C; Galetta D; Metro G; Novello S; Maione P; Colucci G; de Marinis F
Published conference paper: ANNALS OF ONCOLOGY. 2006;17 Suppl 2:ii28-ii31

Locally advanced non-small cell lung cancer: role of induction chemotherapy in resectable N2 disease.

Migliorino MR; De Petris L; De Santis S; Cipri A; Belli R; Condò S; Ariganello O; Di Molfetta M; Saponiero A; de Marinis F
Review: SEMINARS IN ONCOLOGY. 2006;33(1 Suppl 1):S17-S24

Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.

de Marinis F; De Santis S; De Petris L
Review: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2005;331(3):868-880

The role of p53 in treatment responses of lung cancer.

Viktorsson K; De Petris L; Lewensohn R
Review: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(13):3125-3137

Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.

Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
Review: ONCOLOGY-NEW YORK. 2004;18(13 Suppl 8):38-42

Pemetrexed in second-line treatment of non-small-cell lung cancer.

De Marinis F; De Petris L
Review: TUMORI JOURNAL. 2004;3(2):S49-S51

Neoadjuvant strategies for non-small cell lung cancer.

De Marinis F; Migliorino MR; Mancuso A; De Petris L; Belli R
Editorial comment: RECENTI PROGRESSI IN MEDICINA. 2000;91(10):513-516

[Combined treatment of thymoma. State of the art and our experience].

Traficante D; Longo F; Mansueto G; Salerno M; Scirocchi R; De Petris L; Marchei P
Visa fler

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2021-2024

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2010

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI